Page 33 - Clinical Development News Today

Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumpsSubjects utilizing inhaled insulin experienced a...

WILMINGTON, Del., March 11, 2024--Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors. SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Venture Capital firm, Negev Capital, holds a portfolio of companies creating neuropsychiatric drugs based on psychedelic molecules.

On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.

In a bid to reshape the landscape of targeted antibody design, AION a creative venture studio based in Israel has introduced CombinAble.AI.

A conversation between Colin Weller, VP and GM of the evidence platform at Medable and Liza Laws, senior editor, at Outsourcing Pharma, was held at this year’s SCOPE 2024 in Orlando.

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....

Lifebit, a progressive biomedical data technology and services company, has reached a huge milestone, boasting a catalog of 100 million patients in its multi-omic and health data repository.

Being able to identify rare diseases is challenging especially since more than 80% of them have genetic origins.

Operational Progress and Financial Highlights